ViiV Healthcare's N6LS Broadly Neutralizing Antibody Shows Promise in HIV Long-Acting Treatment
• Phase IIb EMBRACE study demonstrates N6LS (VH109), administered every four months with monthly cabotegravir, successfully maintained viral suppression in 96% of participants receiving intravenous treatment.
• The broadly neutralizing antibody was generally well-tolerated, with subcutaneous administration showing more infusion site reactions (14%) compared to intravenous delivery, which reported no such reactions.
• Based on favorable results, ViiV Healthcare is advancing development of a six-month IV formulation of N6LS combined with cabotegravir long-acting for evaluation in the next phase of the EMBRACE trial.
ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025
• Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.
• Long-term follow-up data from multiple studies confirms the sustained efficacy and safety of Cabenuva (cabotegravir + rilpivirine LA) as a complete treatment regimen for people living with HIV.
• Late-breaking phase IIb data reveals promising results for an investigational broadly neutralizing antibody (VH3810109) in combination with cabotegravir LA, potentially expanding long-acting treatment options.
© Copyright 2025. All Rights Reserved by MedPath